SCHEMBL2839620

SCHEMBL2839620

O=S(=O)(c1ccc(Br)cc1)N1CCN(c2cc(Cl)cc(Cl)c2)CC1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
PKM P14618 2/20 0.52
GAA P10253 1/20 0.52
THRB P10828 1/20 0.51
ATM Q13315 1/20 0.50
ALDH1A1 P00352 3/20 0.49
LMNA P02545 2/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PTPN11 Q06124 1/20 0.48
PTGDR Q13258 1/20 0.48
LSS P48449 2/20 0.48
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5327436 0.89 HSD11B1 (0.65) HSD11B1MEN1KMT2APKMGAA
SCHEMBL30005615 0.85 GCK (0.55) HSD11B1MEN1KMT2APKMTHRB
SCHEMBL9344505 0.82 ALDH1A1 (0.65) PKMALDH1A1LMNATSHRHTT
SCHEMBL31315858 0.82 ALDH1A1 (0.65) PKMALDH1A1LMNATSHRHTT
SCHEMBL2836518 0.81 ALDH1A1 (0.72) MEN1KMT2APKMGAATHRB
SCHEMBL9312258 0.80 PKM (0.68) HSD11B1MEN1KMT2APKMALDH1A1
SCHEMBL30005542 0.79 HTT (0.50) HSD11B1MEN1KMT2APKMGAA
SCHEMBL5250380 0.79 HSD11B1 (0.78) HSD11B1MEN1KMT2AGAAATM
SCHEMBL2839187 0.79 MEN1 (0.85) HSD11B1MEN1KMT2APKMGAA
SCHEMBL7956164 0.79 LSS (0.70) MEN1KMT2APKMGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216790-A1 IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS ALTANA PHARMA AG (DE) 2010-08-26 US disclosed
US-7709488-B2 Imidazopyridine-derivatives as inducible no-synthase inhibitors ALTANA PHARMA AG (DE) 2010-05-04 US disclosed
EP-1670796-B1 IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS NYCOMED GMBH (DE) 2008-06-25 EP disclosed
US-20080021039-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors ALTANA PHARMA AG 2008-01-24 US disclosed
US-7279488-B2 Imidazopyridine-derivatives as inducible no-synthase inhibitors NYCOMED GMBH (DE) 2007-10-09 US disclosed
US-20060293302-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors ALTANA PHARMA AG (DE) 2006-12-28 US disclosed
EP-1670796-A1 IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS ALTANA Pharma AG (DE) 2006-06-21 EP disclosed
WO-2005030770-A1 IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS ALTANA PHARMA AG (DE) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293302-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors NOS2, NOS1, NOS3 HSD11B1 1407/4885MEN1 4540/4885KMT2A 2675/4885
US-20080021039-A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors NOS2, NOS1, NOS3 HSD11B1 1407/4885MEN1 4540/4885KMT2A 2675/4885
US-20100216790-A1 IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS NOS2, NOS1, NOS3 HSD11B1 1407/4885MEN1 4540/4885KMT2A 2675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.